Alexander Shifrin, M.D., FACS, FACE, Surgical Director of the Center for Thyroid, Parathyroid and Adrenal Diseases at Jersey Shore University Medical Center, to Present at Prestigious Israeli Medical Forums
Source Newsroom: Meridian Health
Newswise — September 25, 2013 – Neptune, NJ – Alexander Shifrin, M.D., FACS, FACE, surgical director of the Center for Thyroid, Parathyroid and Adrenal Diseases at Jersey Shore University Medical Center, has been invited to present a keynote lecture at The 29th Biennial Conference of the Israel Surgical Association and Israeli Forum of Endocrine Surgery on September 27 at the Israeli Medical Association headquarters in Ramat Gan, Israel. Additionally, Dr. Shifrin will present Molecular Markers in Thyroid Cancer: Changing Surgical Approach at the Department of Surgery Grand Rounds at Kaplan Medical Center in Rehovot, Israel on October 1.
Dr. Shifrin’s key note lecture at the Israeli Forum is entitled Surgery for MEN1 and MEN2 Syndromes in the 21st Century. MEN1 syndrome (multiple endocrine neoplasia type 1 syndrome), also called Wermer's syndrome, is a rare disorder that affects the endocrine system through development of neoplastic lesions in the pituitary, parathyroid gland and pancreas. MEN1 can also cause development of carcinoid tumors in the thymus, bronchus, stomach and small intestine. MEN2 syndrome (multiple endocrine neoplasia type 2 syndrome) is also called Sipple’s Syndrome. It is a hereditary tumor syndrome primarily associated with three types of tumors: medullary thyroid carcinoma, parathyroid tumors, and pheochromocytoma (an adrenal tumor) - in MEN2A syndrome, and medullary thyroid carcinoma, pheochromocytoma, with other features in MEN2B syndrome. Dr. Shifrin’s presentation will highlight extensive research on MEN1 and MEN2, as well as innovative treatments for these conditions.
Additionally, Dr. Shifrin will present Molecular Markers in Thyroid Cancer: Changing Surgical Approach at the Department of Surgery Grand Rounds at Kaplan Medical Center in Rehovot, Israel on October 1. Dr. Shifrin explains the significance of the presentation, “Improvement in the diagnostics and treatment of thyroid nodules has become possible with the introduction of new genetic tests, or molecular markers. We can improve the diagnostic values of the thyroid FNA biopsy by evaluation of molecular markers to rule-in or rule-out thyroid cancer. Some literature even recommends surgical treatment based on markers.”
About Jersey Shore University Medical Center:
Jersey Shore University Medical Center, a member of the Meridian Health family, is a not-for-profit teaching hospital and home to K. Hovnanian Children’s Hospital – the first children’s hospital in Monmouth and Ocean counties. Jersey Shore is the regional provider of cardiac surgery, a program which has been ranked among the best in the Northeast, and is home to the only trauma center and stroke rescue center in the region. Jersey Shore specializes in cardiovascular care, orthopedics and rehabilitation, cancer care, neuroscience, nerve surgery and women’s specialty services. Through the hospital’s clinical research program, and its affiliation with Rutgers Robert Wood Johnson Medical School, Jersey Shore serves as an academic center dedicated to advancing medical knowledge, training future physicians and providing the community with access to promising medical breakthroughs. For more information about Jersey Shore University Medical Center call 1-800-DOCTORS, or visit www.JerseyShoreUniversityMedicalCenter.com